# Tafenoquine Combinations for Improved Radical Cure Efficacy of Plasmodium Vivax

> **NCT07533136** · NA · NOT_YET_RECRUITING · sponsor: **Walter Reed Army Institute of Research (WRAIR)** · enrollment: 300 (estimated)

## Conditions studied

- Uncomplicated P. Vivax Mono-infection

## Interventions

- **DRUG:** Tafenoquine (TQ)
- **DRUG:** Chloroquine (CQ)
- **DRUG:** Dihydroartemisinin-piperaquine (DHA-PPQ)
- **DRUG:** Artemether-lumefantrine (AL)

## Key facts

- **NCT ID:** NCT07533136
- **Lead sponsor:** Walter Reed Army Institute of Research (WRAIR)
- **Sponsor class:** FED
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-05-01
- **Primary completion:** 2028-10-31
- **Final completion:** 2029-05-30
- **Target enrollment:** 300 (ESTIMATED)
- **Last updated:** 2026-04-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07533136

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07533136, "Tafenoquine Combinations for Improved Radical Cure Efficacy of Plasmodium Vivax". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT07533136. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*